Shares of Dr Reddy's Laboratories today rose almost 3 per cent after the company inked a pact with UCB India for distribution and co-promotion of an epilepsy drug in the country.
The Hyderabad-based company's share closed at Rs 2,329.80 after gaining 2.80 per cent. In intra day, it had surged over 3 per cent to touch a high of Rs 2,335.
Similarly on NSE, the stock climbed as much as 2.69 per cent to end at Rs 2,330.10. During the trading session, the stock had touched a high Rs 2,335 and a low of Rs 2,281.95.
In terms of volume, 61,000 shares were traded on BSE and nearly 7.30 lakh shares changed hands on NSE.
In a BSE filling, Dr Reddy's Labs today said it has entered into an agreement with pharma firm UCB India for distribution and co-promotion of Briviact, used for treatment of epilepsy in India.
Briviact (brivaracetam) is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older.
Disclaimer: No Business Standard Journalist was involved in creation of this content
